发布求助
文献互助 智能选刊 最新文献

Lung Cancer Management最新文献

筛选
英文 中文
Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions? 免疫检查点抑制剂在非小细胞肺癌中的再挑战：不同的情况有不同的解决方案？
IF 2.8
Lung Cancer Management Pub Date : 2020-01-16 DOI: 10.2217/lmt-2019-0012
Giulio Metro, Diego Signorelli
{"title":"Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?","authors":"Giulio Metro, Diego Signorelli","doi":"10.2217/lmt-2019-0012","DOIUrl":"10.2217/lmt-2019-0012","url":null,"abstract":"","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2020-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/8e/lmt-08-18.PMC6978724.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37581114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhaled chemotherapy adverse effects: mechanisms and protection methods. 吸入化疗不良反应:机制及保护方法。
IF 2.8
Lung Cancer Management Pub Date : 2020-01-16 DOI: 10.2217/lmt-2019-0007
Chrysanthi Sardeli, Paul Zarogoulidis, Christoforos Kosmidis, Aikaterini Amaniti, Athanasios Katsaounis, Dimitrios Giannakidis, Charilaos Koulouris, Wolfgang Hohenforst-Schmidt, Haidong Huang, Chong Bai, Nikolaos Michalopoulos, Kosmas Tsakiridis, Konstantinos Romanidis, Panagoula Oikonomou, Konstantina Mponiou, Anastasios Vagionas, Alexandru Marian Goganau, Isaak Kesisoglou, Konstantinos Sapalidis
{"title":"Inhaled chemotherapy adverse effects: mechanisms and protection methods.","authors":"Chrysanthi Sardeli,&nbsp;Paul Zarogoulidis,&nbsp;Christoforos Kosmidis,&nbsp;Aikaterini Amaniti,&nbsp;Athanasios Katsaounis,&nbsp;Dimitrios Giannakidis,&nbsp;Charilaos Koulouris,&nbsp;Wolfgang Hohenforst-Schmidt,&nbsp;Haidong Huang,&nbsp;Chong Bai,&nbsp;Nikolaos Michalopoulos,&nbsp;Kosmas Tsakiridis,&nbsp;Konstantinos Romanidis,&nbsp;Panagoula Oikonomou,&nbsp;Konstantina Mponiou,&nbsp;Anastasios Vagionas,&nbsp;Alexandru Marian Goganau,&nbsp;Isaak Kesisoglou,&nbsp;Konstantinos Sapalidis","doi":"10.2217/lmt-2019-0007","DOIUrl":"https://doi.org/10.2217/lmt-2019-0007","url":null,"abstract":"<p><p>Lung cancer is still diagnosed at a late stage due to a lack of symptoms. Although there are novel therapies, many patients are still treated with chemotherapy. In an effort to reduce adverse effects associated with chemotherapy, inhaled administration of platinum analogs has been investigated. Inhaled administration is used as a local route in order to reduce the systemic adverse effects; however, this treatment modality has its own adverse effects. In this mini review, we present drugs that were administered as nebulized droplets or dry powder aerosols for non-small-cell lung cancer. We present the adverse effects and methods to overcome them.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2020-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37581117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Can tumor mutational burden determine the most effective treatment for lung cancer patients? 肿瘤突变负担能否决定肺癌患者最有效的治疗方法?
IF 2.8
Lung Cancer Management Pub Date : 2020-01-14 DOI: 10.2217/lmt-2019-0013
Shixiang Wang, Zaoke He, Xuan Wang, Huimin Li, Tao Wu, Xiaoqin Sun, Kai Wu, Xue-Song Liu
{"title":"Can tumor mutational burden determine the most effective treatment for lung cancer patients?","authors":"Shixiang Wang,&nbsp;Zaoke He,&nbsp;Xuan Wang,&nbsp;Huimin Li,&nbsp;Tao Wu,&nbsp;Xiaoqin Sun,&nbsp;Kai Wu,&nbsp;Xue-Song Liu","doi":"10.2217/lmt-2019-0013","DOIUrl":"https://doi.org/10.2217/lmt-2019-0013","url":null,"abstract":"Graphical abstract","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2020-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37581116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Identifying successful biomarkers for patients with non-small-cell lung cancer 非小细胞肺癌癌症患者的成功生物标志物鉴定
IF 2.8
Lung Cancer Management Pub Date : 2019-11-14 DOI: 10.2217/lmt-2019-0009
A. Friedlaender, J. Bauml, G. Banna, A. Addeo
{"title":"Identifying successful biomarkers for patients with non-small-cell lung cancer","authors":"A. Friedlaender, J. Bauml, G. Banna, A. Addeo","doi":"10.2217/lmt-2019-0009","DOIUrl":"https://doi.org/10.2217/lmt-2019-0009","url":null,"abstract":"Alex Friedlaender1, Joshua Bauml2, Giuseppe Luigi Banna3 & Alfredo Addeo*,1 1Department of Oncology, University Hospital of Geneva (HUG), 12052, Switzerland 2Abramson Cancer Center, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA 191043, USA 3Oncology Department, United Lincolnshire Hospital Trust, Lincoln, LN2 5QY, UK *Author for correspondence: Alfredo.Addeo@hcuge.ch","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2019-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44651007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods 非小细胞肺癌的活检和再活检:当前和未来的方法
IF 2.8
Lung Cancer Management Pub Date : 2019-10-17 DOI: 10.2217/lmt-2019-0006
P. Zarogoulidis, C. Kosmidis, V. Fyntanidou, Z. Aidoni, K. Tsakiridis, Charilaos Koulouris, N. Michalopoulos, Anastasios Barmpas, Hai-dong Huang, C. Bai, W. Hohenforst-Schmidt, K. Sapalidis
{"title":"Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods","authors":"P. Zarogoulidis, C. Kosmidis, V. Fyntanidou, Z. Aidoni, K. Tsakiridis, Charilaos Koulouris, N. Michalopoulos, Anastasios Barmpas, Hai-dong Huang, C. Bai, W. Hohenforst-Schmidt, K. Sapalidis","doi":"10.2217/lmt-2019-0006","DOIUrl":"https://doi.org/10.2217/lmt-2019-0006","url":null,"abstract":"Paul Zarogoulidis*,1, Christoforos Kosmidis1, Varvara Fyntanidou2, Zoi Aidoni1, Kosmas Tsakiridis3, Charilaos Koulouris1, Nikolaos Michalopoulos1, Anastasios Barmpas1, Haidong Huang4, Chong Bai4, Wolfgang Hohenforst-Schmidt5 & Konstantinos Sapalidis1 1Third Department of Surgery, ‘AHEPA’ University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece 2Anesthesiology Department, ‘AHEPA’ University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece 3Thoracic Surgery Department, ‘Interbalkan’ European Medical Center, Thessaloniki, Greece 4Department of Respiratory & Critical Care Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, China 5Sana Clinic Group Franken, Department of Cardiology/Pulmonology/Intensive Care/Nephrology, ‘Hof’ Clinics, University of Erlangen, Hof, Germany *Author for correspondence: pzarog@hotmail.com","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2019-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43285627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study 阿法替尼治疗化疗后携带常见EGFR突变的局部晚期/转移性NSCLC：一项IV期研究
IF 2.8
Lung Cancer Management Pub Date : 2019-09-02 DOI: 10.2217/lmt-2019-0004
S. Thongprasert, Sarayut Lucien Geater, D. Clement, A. Abdelaziz, J. Reyes-Igama, D. Jovanovic, A. Alexandru, M. Schenker, V. Sriuranpong, P. Serwatowski, S. Suresh, A. Cseh, R. Gaafar
{"title":"Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study","authors":"S. Thongprasert, Sarayut Lucien Geater, D. Clement, A. Abdelaziz, J. Reyes-Igama, D. Jovanovic, A. Alexandru, M. Schenker, V. Sriuranpong, P. Serwatowski, S. Suresh, A. Cseh, R. Gaafar","doi":"10.2217/lmt-2019-0004","DOIUrl":"https://doi.org/10.2217/lmt-2019-0004","url":null,"abstract":"Aim: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) following chemotherapy. Patients & methods: In this open-label, single-arm Phase IV study, patients with EGFRm+ (Del19/L858R) NSCLC who had progressed following platinum-based chemotherapy received afatinib (starting dose 40 mg/day). The primary end point was confirmed objective response. Results: 60 patients received afatinib for a median duration of 11.5 months. 50% of patients had a confirmed objective response, of median duration 13.8 months. Median progression-free survival was 10.9 months. The most common treatment-related adverse events were diarrhea (72%), rash (28%) and paronychia (23%). Conclusion: Our data support the use of afatinib (40 mg/day) as an effective and well-tolerated second-line treatment in EGFRm+ NSCLC.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2019-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48795205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity? 神经内分泌阴性的小细胞肺癌和WT RB1型的大细胞神经内分泌癌是同一实体的两面吗?
IF 2.8
Lung Cancer Management Pub Date : 2019-08-21 DOI: 10.2217/lmt-2019-0005
D. Sonkin, Anish Thomas, B. Teicher
{"title":"Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?","authors":"D. Sonkin, Anish Thomas, B. Teicher","doi":"10.2217/lmt-2019-0005","DOIUrl":"https://doi.org/10.2217/lmt-2019-0005","url":null,"abstract":"Until recently, small cell lung cancer (SCLC) was described as SCLC and SCLC variant, based upon cellular morphology and loss of neuroendocrine markers in the SCLC variant. However, based on recent research advances, driven in part by the increase in comprehensive genomic data, it has become clear that there are multiple SCLC subtypes including an ASCL1 and NEUROD1 low, YAP1 high (SCLC-Y) subtype enriched for WT RB1. Comparing morphological and other features of this SCLC subtype to neuroendocrine negative RB1, KEAP1, STK11 WT LCNEC raises a number of important questions with diagnostic and therapeutic implications.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2019-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44348774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid 立体定向放射治疗与分级放射治疗早期支气管肺类癌的比较
IF 2.8
Lung Cancer Management Pub Date : 2019-08-21 DOI: 10.2217/lmt-2019-0003
R. Wegner, S. Abel, Z. Horne, S. Hasan, A. Colonias, V. Verma
{"title":"Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid","authors":"R. Wegner, S. Abel, Z. Horne, S. Hasan, A. Colonias, V. Verma","doi":"10.2217/lmt-2019-0003","DOIUrl":"https://doi.org/10.2217/lmt-2019-0003","url":null,"abstract":"Aim: To compare trends and outcomes in early stage bronchopulmonary carcinoid (BPC) tumors treated nonoperatively with conventionally fractionated radiotherapy (CFRT) and stereotactic body radiotherapy (SBRT). Methods/materials: We queried the National Cancer Database for primary (typical) BPC staged cT1-2N0M0 and treated nonsurgically with lung-directed radiation and ≥1 month of follow-up. Odds ratios were used to predict likelihood of SBRT treatment and multivariable Cox regression determined predictors of survival. Results: Out of 154 patients, 84 (55%) were treated with SBRT and the remainder were treated with CFRT. Although SBRT use was 0% from 2004 to 2007, it varied from 50 to 70% per year thereafter. Propensity-matched Kaplan–Meier analysis revealed improved survival with lung SBRT (median: 66 vs 58 months; p = 0.034). Conclusion: SBRT for early stage, primary BPC has increased over time and was associated with higher survival than CFRT.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2019-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42304463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer 免疫检查点抑制剂治疗癌症挽救性化疗的疗效和安全性
IF 2.8
Lung Cancer Management Pub Date : 2019-05-09 DOI: 10.2217/lmt-2019-0001
M. Tone, T. Izumo, Nobuyasu Awano, N. Kuse, M. Inomata, Tatsunori Jo, Hanako Yoshimura, S. Miyamoto, H. Kunitoh
{"title":"Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer","authors":"M. Tone, T. Izumo, Nobuyasu Awano, N. Kuse, M. Inomata, Tatsunori Jo, Hanako Yoshimura, S. Miyamoto, H. Kunitoh","doi":"10.2217/lmt-2019-0001","DOIUrl":"https://doi.org/10.2217/lmt-2019-0001","url":null,"abstract":"Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2019-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44154321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report 一例转移性非小细胞肺癌癌症患者Pembrolizumab诱导的坏死性肌炎：病例报告
IF 2.8
Lung Cancer Management Pub Date : 2019-05-08 DOI: 10.2217/lmt-2018-0017
Jonas Claus, Annelies Van Den Bergh, Sanne Verbeek, E. Wauters, K. Nackaerts
{"title":"Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report","authors":"Jonas Claus, Annelies Van Den Bergh, Sanne Verbeek, E. Wauters, K. Nackaerts","doi":"10.2217/lmt-2018-0017","DOIUrl":"https://doi.org/10.2217/lmt-2018-0017","url":null,"abstract":"A 57-year-old man presented with swelling and pain in the lower limbs, inability to walk and increasing dyspnea for 2 days. Because of refractory stage IV non-small-cell lung cancer, pembrolizumab was started 21 days before presentation. Since then, he experienced general discomfort, fatigue and bilateral weakness in the legs with exercise limitation. A diagnosis of pembrolizumab-induced grade III myositis was made based on muscle biopsy. Pembrolizumab is a humanized monoclonal antibody against PD-1. It has been approved for the treatment of metastatic melanoma and refractory non-small-cell lung cancer with increased expression of PD-L1 on the cell surface of tumor cells. With such a humanized monoclonal antibody, fewer adverse events are expected than with systemic chemotherapy. However, 13% of patients develop autoimmune side effects which can be severe (grade III, IV or V) in 5–10%. We discuss a case of pembrolizumab-induced myositis, with a brief overview of the literature. Only three cases of pembrolizumab-induced myositis have been reported in literature.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2019-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2018-0017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47627281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信